Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain

被引:142
作者
Bruera, E
Belzile, M
Pituskin, E
Fainsinger, R
Darke, A
Harsanyi, Z
Babul, N
Ford, I
机构
[1] Univ Alberta, Grey Nuns Community Hosp & Hlth Ctr, Cross Canc Inst, Div Palliat Care Med,Palliat Care Program, Edmonton, AB T6L 5X8, Canada
[2] Dept Sci Affairs, Pickering, ON, Canada
关键词
D O I
10.1200/JCO.1998.16.10.3222
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Use of oxycodone for chronic cancer pain has been hampered by its short elimination half-life. This study was designed to compare the efficacy and safety of controlled-release formulations of oxycodone and morphine for cancer pain. Patients and Methods: Thirty-two adult patients with cancer pain and a greater than or equal to 3-day history of stable analgesia with oral opioids provided written informed consent and were randomized to controlled-release oxycodone or controlled-release morphine for 7 days. To blind the study using available tablet strengths, the dose ratio of oxycodone to morphine was set at 1:1.5, On day 8, patients were crossed over to the alternate drug for 7 days. Pain intensity was assessed using a visual analog scale (VAS 0 to 100 mm) and a categorical scale (CAT 0 to 4), Side effects were assessed using a checklist (four-point categorical severity) and a nondirected questionnaire, Patients and investigators made blinded global ratings af efficacy and treatment preference. Results: Twenty-three patients completed the study (10 men, 13 women). The VAS and CAT scores were (mean +/- SD) 23 +/- 21 and 1.2 +/- 0.8 On controlled-release oxycodone, and 24 +/- 20 (P =.43) and 1.3 +/- 0.7 (P =.36) on controlled release morphine. No period or carryover effect was detected. There were no significant differences in adverse effects (P =.40) or ratings of efficacy and preference, The median oxycodone/morphine dose ratio was 1.5 and the maximum was 2.3. Conclusion: Controlled release oxycodone is as safe and effective as controlled-release morphine in the treatment of cancer pain. (C) 1998 by American Society of Clinical Oncology.
引用
收藏
页码:3222 / 3229
页数:8
相关论文
共 53 条
[1]   Comparative efficacy and safety of controlled-release morphine suppositories and tablets in cancer pain [J].
Babul, N ;
Provencher, L ;
Laberge, F ;
Harsanyi, Z ;
Moulin, D .
JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 38 (01) :74-81
[2]  
BEAVER WT, 1978, J PHARMACOL EXP THER, V207, P92
[3]  
BEAVER WT, 1978, J PHARMACOL EXP THER, V207, P101
[4]  
BENZIGER DP, 1996, P 8 WORLD C PAIN VAN
[5]  
BONICA JJ, 1979, ADV PAIN RES THER, P1
[6]   STEADY-STATE PHARMACOKINETIC EVALUATION OF A NOVEL, CONTROLLED-RELEASE MORPHINE SUPPOSITORY AND SUBCUTANEOUS MORPHINE IN CANCER PAIN [J].
BRUERA, E ;
FAINSINGER, R ;
SPACHYNSKI, K ;
BABUL, N ;
HARSANYI, Z ;
DARKE, AC .
JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 35 (07) :666-672
[7]   CHANGING PATTERN OF AGITATED IMPAIRED MENTAL STATUS IN PATIENTS WITH ADVANCED CANCER - ASSOCIATION WITH COGNITIVE MONITORING, HYDRATION, AND OPIOID ROTATION [J].
BRUERA, E ;
FRANCO, JJ ;
MALTONI, M ;
WATANABE, S ;
SUAREZALMAZOR, M .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1995, 10 (04) :287-291
[8]   THE EDMONTON STAGING SYSTEM FOR CANCER PAIN - PRELIMINARY-REPORT [J].
BRUERA, E ;
MACMILLAN, K ;
HANSON, J ;
MACDONALD, RN .
PAIN, 1989, 37 (02) :203-209
[9]   CIRCADIAN DISTRIBUTION OF EXTRA DOSES OF NARCOTIC ANALGESICS IN PATIENTS WITH CANCER PAIN - A PRELIMINARY-REPORT [J].
BRUERA, E ;
MACMILLAN, K ;
KUEHN, N ;
MILLER, MJ .
PAIN, 1992, 49 (03) :311-314
[10]   CLINICAL EFFICACY AND SAFETY OF A NOVEL CONTROLLED-RELEASE MORPHINE SUPPOSITORY AND SUBCUTANEOUS MORPHINE IN CANCER PAIN - A RANDOMIZED EVALUATION [J].
BRUERA, E ;
FAINSINGER, R ;
SPACHYNSKI, K ;
BABUL, N ;
HARSANYI, Z ;
DARKE, AC .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (06) :1520-1527